IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Peer Comparison
Peer Comparison
Performance
Performance Report
Beta Drugs IPO is a Fixed Price listing on NSE EMERGE exchange, with an ipo size of ₹ 19.52 Cr. The company is based in Baddi and caters to Pharmaceutical sector. Pantomath Capital Advisors is the merchant banker of Beta Drugs IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 28th August 2017.
Beta Drugs IPO posted revenues of ₹ 41.65 Cr. and PAT of ₹ 5.17 Cr. in FY17 on annualised basis.
Revenue:
₹ 41.65 Cr.
EBITDA Margin:
17.33
% 
Net Worth: ₹ 7.38 Cr.
Market Capitalisation:
[●]
P/E:
14.00 times
P/BV: [●]
EV/EBITDA: 1.02 times
Financial results of Beta Drugs IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | Mar-17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 24.54 | 15.20 | 8.00 | 1.35 | |
| Net Worth | 7.38 | 2.20 | 1.06 | 0.18 | |
| Total Debt | 7.51 | 7.74 | 4.36 | 0.96 | |
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
41.65
41.65 |
26.37 | 0.26 | 1.38 | |
EBITDA
EBITDA on annualised basis |
7.22
7.22 |
3.02 | [●] | 0.18 | |
PAT
PAT on annualised basis |
5.17
5.17 |
1.13 | 0.11 | 0.02 | |
Beta Drugs IPO PAT Margin is 12.41 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows Beta Drugs IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | Mar-17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|
| EBITDA Margin (%) | 17.33 | 11.45 | [●] | 13.04 |
| PAT Margin (%) | 12.41 | 4.29 | 42.31 | 1.45 |
| EPS (₹) | 8.69 | 1.90 | -0.19 | 0.04 |
| ROE (%) | 70.05 | 51.36 | 10.38 | 11.11 |
| ROCE (%) | [●] | [●] | [●] | [●] |
| ROA (%) | 21.07 | 7.43 | 1.38 | 1.48 |
| Debt to Equity | 1.02 | 3.52 | 4.11 | 5.33 |
The market Capitalisation of Beta Drugs IPO is ₹ 0.00 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Beta Drugs IPO prospectus highlights an Return on Equity (ROE) of 70.05 % , Return on Assets (ROA) of 21.07 %, and an EBITDA Margin of 17.33 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Beta Drugs IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Beta Drugs IPO is ₹ 0.00 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Beta Drugs IPO has a Price-to-Earnings (PE) ratio of 14.00 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Beta Drugs IPO reported revenue of ₹ 41.68 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Beta Drugs IPO provide insights into sales growth, market demand, and business scalability.
Beta Drugs recorded an EBITDA of ₹ 7.22 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Beta Drugs Profit After Tax (PAT) is ₹ 5.17 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 41.65 Cr.
EBITDA Margin:
17.33
%
Net Worth: ₹ 7.38 Cr.
Market Capitalisation:
[●]
P/E:
14.00 times
P/BV: [●]
EV/EBITDA:
[●]
Beta Drugs operates in Pharmaceutical and Manufacturing Of Its Leading Anticancer Cyto-toxics. The Issue is listed on NSE EMERGE in Oct, 2017. Beta Drugs IPO size was 19.52 with Issue price of 85.00 .
Merchant Banker(s) of Beta Drugs IPO: Pantomath Capital Advisors Private Limited
Beta Drugs IPO subscription was 0.00 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Beta Drugs IPO listed at a listing price of 101.95 against the offer price of 85.00.
The current market price of Beta Drugs is 1682.00.
Why Us?
